1. Home
  2. WRN vs EDIT Comparison

WRN vs EDIT Comparison

Compare WRN & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WRN
  • EDIT
  • Stock Information
  • Founded
  • WRN 2006
  • EDIT 2013
  • Country
  • WRN Canada
  • EDIT United States
  • Employees
  • WRN N/A
  • EDIT N/A
  • Industry
  • WRN Metal Mining
  • EDIT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • WRN Basic Materials
  • EDIT Health Care
  • Exchange
  • WRN Nasdaq
  • EDIT Nasdaq
  • Market Cap
  • WRN 248.0M
  • EDIT 263.7M
  • IPO Year
  • WRN N/A
  • EDIT 2016
  • Fundamental
  • Price
  • WRN $1.33
  • EDIT $3.03
  • Analyst Decision
  • WRN Strong Buy
  • EDIT Buy
  • Analyst Count
  • WRN 1
  • EDIT 12
  • Target Price
  • WRN $4.00
  • EDIT $5.40
  • AVG Volume (30 Days)
  • WRN 407.5K
  • EDIT 2.5M
  • Earning Date
  • WRN 08-08-2025
  • EDIT 08-12-2025
  • Dividend Yield
  • WRN N/A
  • EDIT N/A
  • EPS Growth
  • WRN N/A
  • EDIT N/A
  • EPS
  • WRN N/A
  • EDIT N/A
  • Revenue
  • WRN N/A
  • EDIT $38,901,000.00
  • Revenue This Year
  • WRN N/A
  • EDIT N/A
  • Revenue Next Year
  • WRN N/A
  • EDIT N/A
  • P/E Ratio
  • WRN N/A
  • EDIT N/A
  • Revenue Growth
  • WRN N/A
  • EDIT N/A
  • 52 Week Low
  • WRN $0.90
  • EDIT $0.91
  • 52 Week High
  • WRN $1.42
  • EDIT $4.19
  • Technical
  • Relative Strength Index (RSI)
  • WRN 58.21
  • EDIT 59.27
  • Support Level
  • WRN $1.20
  • EDIT $2.07
  • Resistance Level
  • WRN $1.30
  • EDIT $3.17
  • Average True Range (ATR)
  • WRN 0.05
  • EDIT 0.24
  • MACD
  • WRN 0.00
  • EDIT 0.02
  • Stochastic Oscillator
  • WRN 88.72
  • EDIT 87.27

About WRN Western Copper and Gold Corporation

Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project).

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: